Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tozorakimab · MEDI-3506

Monoclonal antibody · developed by ASTRAZENECA

Phase 3 Most advanced trial
AZN Developer

What is Tozorakimab?

Tozorakimab (MEDI3506) is an antibody given as a single intravenous dose. It is studied in viral lung infection and acute respiratory failure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MEDI-3506
Drug type
Monoclonal antibody
Therapy area
Infectious disease, Respiratory
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
OHZ2MEL7FD

Conditions studied

Viral Lung Infection and Acute Respiratory Failure

More from ASTRAZENECA

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Tozorakimab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.